Clinical trials: sponsored by Merck Sharp & Dohme LLC
Head and Neck Cancer
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer.
- Trial name
- NCT02641093
- Testing
- Pembrolizumab, Surgery, Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Trisha Wise-Draper
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week…
- Trial name
- NCT05612035
- Testing
- Frespaciguat
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial.
- Trial name
- PAM-II (NCT06180733)
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Urinary Bladder Neoplasms
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body.
- Trial name
- NCT04241185
- Testing
- Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes)
- Where
- 134 sites in United States, Australia and 23 more
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Colorectal Adenocarcinoma
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
The purpose of this research study is: To find out how safe the study drug, pembrolizumab, is when combined with stereotactic body radiotherapy (SBRT) to the liver.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02837263
- Testing
- Stereotactic body radiotherapy (SBRT), Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Chronic Kidney Diseases, Kidney Transplant
Immunogenicity of HPV Vaccine in Transplant Recipients.
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
- Trial name
- NCT05557370
- Testing
- Human Papilloma Virus vaccine (GARDASIL 9)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Adverse Drug Reaction (ADR)
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to…
- Trial name
- NCT00414115
- Where
- Canada
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Cancer, Tumor, Solid
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05378425
- Testing
- NTX-1088, Pembrolizumab
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 90 people
- Sponsor
- Nectin Therapeutics Ltd
Hematological Malignancies
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.
- Trial name
- NCT05347225
- Testing
- Nemtabrutinib
- Where
- 5 sites in China
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir…
- Trial name
- ISLEND-1 (NCT06630286)
- Testing
- ISL/LEN, B/F/TAF, PTM B/F/TAF
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 609 people
- Sponsor
- Gilead Sciences
Bipolar I Disorder
A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
- Trial name
- NCT06273774
- Testing
- Elpipodect
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
- Trial name
- NCT05227118
- Testing
- Elpipodect
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens.
- Trial name
- NCT04506905
- Testing
- Elpipodect
- Where
- 6 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to…
- Trial name
- NCT04206813
- Testing
- Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Schizophrenia
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.
- Trial name
- NCT05406440
- Testing
- Elpipodect
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
The purpose of this study was to evaluate the efficacy and safety of elpipodect at a range of doses (8 mg, 16 mg, and 24 mg once daily [QD]) in adult participants who have an acute episode of schizophrenia according to Diagnostic…
- Trial name
- NCT04624243
- Testing
- Elpipodect, Risperidone
- Where
- 121 sites in United States, Bulgaria and 10 more
- Volunteers
- 499 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg elpipodect on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily…
- Trial name
- TQT (NCT05893862)
- Testing
- Elpipodect, Moxifloxacin
- Where
- 4 sites in United States
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.